| - |
Tadalafil |
Adcirca® |
In adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity. |
Rapid Review Complete |
27th May 2014 |
 |
| 20017 |
Tafamidis |
Vyndaqel® |
For the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy. |
Assessment process complete |
25th September 2020 |
|
| - |
Tafamidis meglumine |
Vyndaqel® |
For the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment. |
Rapid Review Complete |
10th May 2018 |
|
| 22008 |
Tafasitamab |
Minjuvi® |
In combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT). |
Rapid Review Complete |
15th February 2022 |
|
| - |
Tafluprost |
Saflutan® |
For the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. |
Rapid Review Complete |
9th April 2011 |
|
| 19032 |
Talazoparib |
Talzenna® |
As monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. |
Assessment process complete |
18th September 2020 |
|
| 23074 |
Talazoparib |
Talzenna® |
Talazoparib (Talzenna®) in combination with enzalutamide is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. |
Rapid Review Complete |
21st December 2023 |
|
| - |
Talimogene laherparepvec |
Imlygic® |
For the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. |
Rapid Review Complete |
15th March 2016 |
|
| 23057 |
Talquetamab |
Talvey® |
Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
Full HTA submission received from Applicant |
2nd May 2024 |
|
| - |
Tapentadol |
Palexia® |
For the management of adult patients with severe chronic/acute pain. |
Assessment process complete |
13th April 2011 |
|
| 23064 |
Tebentafusp |
Kimmtrak® |
Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. |
Rapid Review Complete |
13th November 2023 |
|
| 22064 |
Teclistamab |
Tecvayli® |
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
4th July 2024 |
|
| - |
Tedizolid phosphate |
Sivextro® |
For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults |
Rapid Review Complete |
7th July 2015 |
|
| - |
Teduglutide |
Revestive® |
For the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation. |
Assessment process complete |
16th March 2018 |
|
| __ |
Tegafur/Gimeracil/Oteracil |
Teysuno® |
For the treatment of advanced gastric cancer. |
Rapid Review Complete |
31st March 2012 |
|
| - |
Telaprevir |
Incivo® |
As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
Assessment process complete |
19th January 2012 |
|
| __ |
Telavancin |
Vibativ® |
For the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA). Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable. |
Rapid Review Complete |
13th January 2015 |
|
| 22025 |
Tepotinib |
Tepmetko® |
For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
NCPE Assessment Process Complete |
29th November 2023 |
|
| - |
Teriflunomide |
Aubagio® |
For the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS). |
Assessment process complete |
19th June 2014 |
|
| - |
Ticagrelor |
Brilique® |
For the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft). |
Assessment process complete |
11th October 2011 |
|
| - |
Ticagrelor |
Brilique® |
Co-administered with acetylsalicylic acid (ASA), for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event. |
Rapid Review Complete |
5th May 2016 |
|
| 19029 |
Tildrakizumab |
Ilumetri® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Assessment process complete |
25th November 2021 |
|
| 21054 |
Tirbanibulin |
Klisyri® |
For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. |
Rapid Review Complete |
30th November 2021 |
|
| 24003 |
Tirzepatide |
Mounjaro® |
Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
Pre submission consultation scheduled |
6th February 2024 |
|
| 24024 |
Tirzepatide |
(Mounjaro®) |
For chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). |
Awaiting full HTA submission from Applicant |
15th October 2024 |
|
| - |
Tisagenlecleucel |
Kymriah® |
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. |
Assessment process complete |
20th September 2019 |
|
| - |
Tisagenlecleucel |
Kymriah® |
For the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. |
Assessment process complete |
27th August 2019 |
|
| 22044 |
Tisagenlecleucel |
Kymriah® |
For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
NCPE Assessment Process Complete |
12th August 2024 |
|
| - |
Tivozanib |
Fotivda® |
For the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. |
Rapid Review Complete |
24th January 2019 |
|
| 22015 |
Tixagevimab /cilgavimab |
Evusheld® |
For the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg. |
NCPE Assessment Process Complete |
22nd December 2022 |
|
| 22074 |
Tixagevimab/cilgavimab |
Evusheld® |
Is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
Rapid Review Complete |
25th January 2023 |
|
| - |
Tobramycin |
TOBI Podhaler® |
For the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF. |
Rapid Review Complete |
29th November 2010 |
|
| - |
Tocilizumab SC |
RoActemra® |
For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate. |
Rapid Review Complete |
16th July 2014 |
|
| 21034 |
Tofacitinib |
Xeljanz® |
For the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. |
Rapid Review Complete |
8th September 2021 |
|
| 22005 |
Tofacitinib |
Xeljanz® |
For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. |
Rapid Review Complete |
8th March 2022 |
|
| - |
Tofacitinib |
Xeljanz® |
For the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor). |
Rapid Review Complete |
18th September 2018 |
|
| - |
Tolvaptan |
Jinarc® |
To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease. |
Assessment process complete |
13th September 2018 |
|
| 21028 |
Tralokinumab |
Adtralza® |
For the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy. |
Rapid Review Complete |
29th July 2021 |
|
| - |
Tramadol hydrochloride/dexketoprofen |
Skudexa® |
For the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen. |
Rapid Review Complete |
1st December 2017 |
|
| - |
Trametinib |
Mekinist® |
For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
Assessment process complete |
15th March 2017 |
|
| 22050 |
Trastuzumab deruxtecan |
Enhertu® |
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. |
NCPE Assessment Process Complete |
12th December 2023 |
|
| 23011 |
Trastuzumab deruxtecan |
Enhertu® |
Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. |
NCPE Assessment Process complete |
30th September 2024 |
|
| 24028 |
Trastuzumab deruxtecan |
Enhertu® |
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. |
Rapid Review Complete |
21st August 2024 |
|
| - |
Trastuzumab emtansine |
Kadcyla® |
For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination. |
Assessment process complete |
1st July 2014 |
|
| 20002 |
Trastuzumab emtansine |
Kadcyla® |
As a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. |
Assessment process complete |
12th March 2021 |
|
| 23073 |
Tremelimumab |
Imjudo® |
Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. |
Full HTA submission received from Applicant |
16th July 2024 |
|
| - |
Trientine Tetrahydrochloride (TETA 4HCL) |
Cuprior® |
For the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy. |
Rapid Review Complete |
9th October 2019 |
|
| - |
Trifluridine/tipiracil |
Lonsurf® |
For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. |
Rapid Review Complete |
13th July 2016 |
|
| 22011 |
Trifluridine/tipiracil |
Lonsurf® |
As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. |
Rapid Review Complete |
15th March 2022 |
|
| 22058 |
Tucatinib |
Tukysa® |
In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
Full HTA submission received from Applicant |
14th March 2024 |
|
